ASCRS $1 million better off

Article

Advanced Medical Optics (AMO) has pledged $1 million to support the American Society of Cataract and Refractive Surgery's (ASCRS) foundation sponsored research in the field of refractive lenticular science.

Advanced Medical Optics (AMO) has pledged $1 million to support the American Society of Cataract and Refractive Surgery's (ASCRS) foundation sponsored research in the field of refractive lenticular science.

The ASCRS Foundation funds ophthalmic research, public education and charitable activities in the developing world and in 2006 it is due to begin work on a multi-year programme supporting new research and educational programmes exploring the science of refractive lenticular surgery.

Re-brand for Ellex Medical Lasers

Ellex is to replace the brand "Laserex" and the company's US and Japanese subsidiaries will also adopt the name. The company is also due to relocate its global headquarters responsible for sales, marketing and customer services to San Francisco, US, in a move, that it says, will bring it closer to its three main markets of North America, North Asia and Europe. Ellex's manufacturing, engineering and finance operations will remain in Adelaide, Australia.

Ellex designs and manufactures various laser systems for the ophthalmic industry including photodisrupters, photocoagulators and selective laser trabeculoplasty systems.

Carl Zeiss Meditec to grow: not yet

At the company's fourth Annual General Meeting, more than 99% of the shareholders supported the initiative. Despite this broad approval, a small number lodged objections against the acquisition and all other items on the agenda. As a result, eight shareholders have now filed legal actions against the planned acquisition, which appears to have delayed the approval procedure. Nonetheless, Carl Zeiss Meditec's intention to acquire Carl Zeiss Surgical remains unchanged.

The acquisition is likely to make Carl Zeiss Meditec the third largest listed medical technology company in Germany.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.